Recombinant Protein Vaccine With Homogeneous Multi-Epitope Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments using recombinant vaccines face challenges due to chemical conjugation methods that hinder immune responses and result in heterogeneous products, leading to potential auto-immune diseases and limited efficacy.
Innovation Solution
Development of homogeneous recombinant proteins expressing tumor antigens, growth factors, and receptors in a natural conformation, using cholera toxin B (CT-B) or synthetic equivalents, to elicit a robust immune response by presenting multiple epitopes and binding sites, with controlled multimerization and administration strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If chemical conjugation methods are used to create recombinant vaccines, then the vaccines can be manufactured, but the immune response is hindered and heterogeneous products are formed
Solution Approach 1:
The patent employs homogeneous recombinant proteins where multiple copies of tumor antigens, growth factors, and receptors are genetically fused to a carrier protein in a controlled manner. This ensures uniform presentation of epitopes and binding sites, eliminating the heterogeneity caused by chemical conjugation while maintaining manufacturability through recombinant expression systems.
Solution Approach 2:
The vaccine is designed as a segmented recombinant protein structure where a carrier protein is genetically fused with multiple copies of specific tumor antigens, growth factors, and receptors. This segmentation allows controlled multimerization through genetic design rather than random chemical conjugation, ensuring homogeneous products with defined epitope presentations.
2Quantity of substance
If chemical conjugation is used to present multiple epitopes, then antigen presentation is enhanced, but heterogeneous products result leading to potential auto-immune diseases
Solution Approach 1:
The recombinant protein structure ensures homogeneous presentation of multiple epitopes through controlled genetic fusion, where each carrier protein molecule presents an identical number and arrangement of tumor antigens, growth factors, and receptors. This uniformity prevents the formation of heterogeneous products that could trigger auto-immune responses.
Solution Approach 2:
Multiple copies of tumor antigen epitopes, growth factor sequences, and receptor domains are genetically replicated and fused to the carrier protein in a controlled manner. This copying approach ensures consistent epitope presentation across all vaccine molecules, enhancing immune recognition while maintaining product homogeneity and safety.
3Productivity
If heterogeneous recombinant products are produced, then manufacturing is simplified, but treatment efficacy is limited and safety is compromised
Solution Approach 1:
The patent achieves homogeneous recombinant protein products through controlled genetic fusion, where a carrier protein is fused with defined numbers of tumor antigen copies, growth factor sequences, and receptor domains. This homogeneous structure ensures consistent immunogenicity and treatment efficacy while remaining manufacturable through standard recombinant expression systems.
Data Source
AI summary
A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats.